SuperworthSilence Therapeutics revenue SLN
Sales by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jun 30, 2026
- $615K
- Latest quarter, Q2 FY26
- $0
- −100% on a year earlier
- Fiscal year 2025
- $559K
- −99% on the year before
Silence Therapeutics' revenue was $615K over the twelve months to Jun 30, 2026, down 98% on a year earlier.
In its latest quarter, Q2 FY26, it was $0, down 100% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $559K | −99% |
| FY2024 | $43.3M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0 | −100% | $615K | |
| Q1 FY26 | $422K | +197% | $839K | |
| Q4 FY25 | $34K | −100% | $559K | |
| Q3 FY25 | $159K | −89% | $25.8M | |
| Q2 FY25 | $224K | −70% | $27.2M | |
| Q1 FY25 | $142K | −99% | $27.7M | |
| Q4 FY24 | $25.3M | n/a | $43.3M | |
| Q3 FY24 | $1.5M | n/a | n/a | |
| Q2 FY24 | $756K | n/a | n/a | |
| Q1 FY24 | $15.7M | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Silence Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| SLNSilence Therapeutics | $615K | −98% a year |
| ABUSArbutus Biopharma | $181.7M | |
| AMPHAmphastar Pharmaceuticals | $730M | +1% a year |
| COLLCollegium Pharmaceutical | $808.2M | +14% a year |
| OMEROmeros | n/m | |
| CRMDCorMedix | $462.2M | +281% a year |
| PCRXPacira BioSciences | $746.2M | +6% a year |
| ANABAnaptysbio | n/m | |
| ZVRAZevra Therapeutics | $136.1M | +119% a year |
| IRWDIronwood Pharmaceuticals | $389.3M | +26% a year |
| PBYIPuma Biotechnology | $231.2M | −3% a year |
| Peer median | $425.8M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Silence Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.